ReviewJournal of robotic surgery2026
CT prostate angiogram for nerve-sparing robot-assisted radical prostatectomy.
Review in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRobot-assisted radical prostatectomy (RARP) is a widely used treatment for clinically localised prostate cancer. Preserving neurovascular bundles (NVB), are crucial for erectile function and urinary continence. However, it remains challenging due to accurate identification of the NVB. Branches of the prostatic artery can act as a reference for nerve-sparing (NS) prostatectomy surgery. Due to anatomical variations, vascular mapping utilising CT prostate angiography (CTPA) could assist in prostate artery localisation during RARP, to impact surgical outcomes.
aimsThis is a hypothesis-generating narrative review in which the anatomy of the prostate, NVB and vasculature is described in addition to the current scope of RARP. CTPA in preoperative planning for RARP is evaluated, with a focus on its potential to enhance preservation of erectile function through improved identification of prostatic vasculature. DISCUSSION: CTPA is used for pre-procedure planning in prostate artery embolization (PAE) to manage symptomatic benign prostatic hyperplasia (BPH). Currently, pre-procedure planning for NS RARP includes prostate biopsy and MRI for staging. The mainstay of research on RARP is primarily focused on techniques to preserve the NVB, but the role of arterial anatomy warrants additional exploration. Factors such as cost, time and radiation exposure must be considered before CTPA could be included in routine preoperative assessment.
conclusionBy enabling precise identification of critical prostate arterial anatomy, CTPA could facilitate easier localization of the NVB intraoperatively, contributing to improved surgical outcomes. Further investigations are required to ascertain if preoperative CTPA can be a standard to improve functional outcomes and recovery after RARP.
Indexed as
Identifiers
41563651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.